Neurana Pharmaceuticals, Inc. today announced participation at the SVB Leerink Biopharma Private Company Connect. The conference takes place virtually July 21st -22 nd.
| SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced participation at the SVB Leerink Biopharma Private Company Connect. The conference takes place virtually July 21st-22nd. Presentations will be available for registered attendees via the SVB Leerink conference site. About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana’s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. For additional information, please visit www.neuranapharma.com.
SOURCE Neurana Pharmaceuticals, Inc. |
View original content:
